Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, announced that Shreehas Tambe, Deputy CEO of Biocon Biologics, has been appointed as the Managing Director and CEO of the Company. Mr Tambe will lead BBL in realizing its goal of being a global biosimilars leader.

Mr Tambe takes over from Dr Arun Chandavarkar, who will continue to serve as a non-Executive, non-Independent Director on the Board of Biocon Biologics.

Welcoming Mr Tambe, Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics, said, “I am extremely pleased that Shreehas is taking on the responsibility of leading Biocon Biologics as MD & CEO at a time when the company is gearing up for global leadership in biosimilars with the closing of the Viatris acquisition. His demonstrated track record of business success, deep technical and operational expertise provide him with proven leadership capabilities to assume this role. Shreehas will be aided by a highly experienced Executive Leadership Team in building a future-ready, world leading biosimilars player and a well-recognized global brand that is committed to impact global healthcare. I extend my best wishes to him for a successful journey ahead.”

BBL has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of its partner Viatris Inc. in November 2022. BBL and Viatris have obtained all applicable approvals from key global regulators including the U.S. Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors.

Effective from November 29, 2022, BBL will recognize the combined revenue and associated profits from the acquired products, a step-up from the existing profit share arrangement.

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, announced that Shreehas Tambe, Deputy CEO of Biocon Biologics, has been appointed as the Managing Director and CEO of the Company. Mr Tambe will lead BBL in realizing its goal of being a global biosimilars leader.